Merck

Variational AI is a preclinical therapeutics company that leverages advanced machine learning techniques to efficiently generate novel compounds optimized for various properties, thereby addressing common challenges in drug development. The company focuses on creating selective kinase inhibitors for solid tumors while also exploring additional target classes. By collaborating with leading biopharmaceutical partners, Variational AI aims to streamline the drug discovery process, enabling these partners to conduct multi-property molecular optimization. This approach significantly reduces the time needed to identify drug-like molecules with a higher likelihood of success in clinical trials. In addition to its collaborations, Variational AI is also developing its own internal pipeline of therapeutic candidates.

HD is a healthcare and surgery marketplace, powering over 1,500+ healthcare providers including some of the biggest hospitals. HD connects patients to hospitals, clinics, operating rooms, and surgeons while offering healthcare financing solutions to increase access to affordable care and surgeries. To date, over 250,000 patients have benefited from more accessible and affordable healthcare and surgeries through the company's platform.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Personalis, Inc. is a cancer genomics company that specializes in sequencing and data analysis services to facilitate the development of personalized cancer therapies. The company offers the NeXT Platform, which delivers critical data for therapy development, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that analyzes various human genes. Its services cater to a diverse clientele, including biopharmaceutical companies, academic institutions, non-profit organizations, diagnostics firms, and government agencies. The company focuses on advancing precision medicine and immunotherapy by providing detailed molecular insights into individual tumors and their interactions with the immune system. Founded in 2011 and headquartered in Menlo Park, California, Personalis has established partnerships to enhance its offerings and expand its impact in cancer treatment.

Modifi Biosciences specializes in direct DNA modification and the creation of innovative cancer therapeutics. The company's primary focus is on altering tumor DNA in a way that makes cancer cells irreparable while preserving healthy cells. This distinctive methodology allows researchers to challenge and transform traditional approaches to oncology drug development. By exploiting DNA defects across various cancer types, Modifi Biosciences aims to provide effective treatments that target the underlying genetic issues in tumors, thereby advancing the field of cancer therapeutics.

Ash is a leading at-home health testing platform expanding care to reach those most in need. Working closely with our partners, we tailor end-to-end testing solutions that meet the unique needs of any health organization’s population. Our strength comes from our unmatched understanding of people—whether that means learning the best ways to reach them or innovating a new way to keep them connected and cared for. We use our deep knowledge to develop field-tested best practices that engage hard-to-reach patients and members where they are. Because when people come first, better health outcomes are possible for all.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

CargoSense, Inc. is a Software-as-a-Service (SaaS) company that specializes in logistics oversight solutions for supply chain networks. Founded in 2012 and based in Reston, Virginia, the company utilizes data-driven technology to provide visibility into the transportation of sensitive goods such as pharmaceuticals and food. Its suite of applications includes CARGOSENSE SUPPLY for cold chain management, CARGOSENSE FRESH for compliance with health regulations, CARGOSENSE CLINICAL for clinical trials, and CARGOSENSE CONTROL for real-time monitoring of shipments. The company also offers FridgeSense, a cloud-based analytics tool for climate control, as well as logistics beacons and custom reporting services. CargoSense’s solutions help clients in transportation, life sciences, third-party logistics, electronics, and food and beverage industries to enhance compliance, lower shipping costs, and minimize product loss by providing comprehensive insights into shipment conditions, including temperature and environmental factors.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Friends of Puerto Rico is a nonpartisan, non-profit social impact group that advocates for economic growth. and education through result-oriented entrepreneurial ventures centered on sustainability and self-sufficiency.

Atropos Health is a technology company based in Palo Alto, California, founded in 2019. It specializes in developing a digital prognostogram platform, known as the Atropos Evidence Platform, which transforms health data into actionable real-world evidence. By integrating electronic medical record (EMR) data, the platform generates digital evidence tailored to individual patient outcomes. This enables healthcare institutions, life science companies, and researchers to utilize previously siloed EMR data effectively. The platform aims to close evidence gaps in healthcare, enhance clinical outcomes through data-driven care, and accelerate research initiatives. Atropos Health serves caregivers, healthcare organizations, and risk-bearing entities, contributing to advancements in evidence-based healthcare.

N-Power Medicine is a biotechnology company focused on advancing drug development and clinical research, particularly within the field of oncology. The company operates a network of community oncology centers staffed with qualified professionals who assist in identifying suitable patients for research studies. This approach not only accelerates the pace of clinical trials but also aims to enhance the diversity of patient populations involved in these studies. By facilitating faster and more efficient research processes, N-Power Medicine aims to support pharmaceutical companies and researchers in their efforts to innovate and improve cancer treatment options.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Abceutics operates as a biopharmaceutical company.

Baseimmune is a biotech startup focused on developing the next generation of vaccines. The company has created a platform for pathogen analysis that facilitates the design of antigens and vaccines. Utilizing advanced technology, Baseimmune's platform enables the generation of antigens with a high level of informatics depth, allowing for effective responses to emerging and challenging pathogens. This capability ensures that healthcare providers can maintain vaccine efficacy even in the face of pathogen mutations.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, specializing in drug discovery through the innovative use of macrocyclic peptides. Founded in 2016, the company employs artificial intelligence and computational biology techniques to engineer these peptides, allowing them to target previously undruggable protein interactions. By leveraging machine learning for parallel chemical synthesis, Unnatural Products aims to optimize macrocyclic compounds efficiently, thereby accelerating the drug discovery process. This technology addresses a significant gap in therapeutic strategies, offering potential treatments for a wide range of diseases linked to difficult-to-target drug candidates.

Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company headquartered in San Diego, California, focused on developing and commercializing innovative products for individualized patient care, particularly in gastroenterology. Founded in 1995, the company offers a range of diagnostic tests, including Anser IFX and Anser ADA assays for monitoring drug and anti-drug antibody levels, as well as various tests for inflammatory bowel disease, celiac disease, and lactase intolerance. Their product lineup includes therapeutic monitoring tools, such as Anser UST for patients treated with Stelara, and diagnostic tests that utilize a proprietary algorithm to improve accuracy in patient assessments. Additionally, Prometheus Laboratories markets pharmaceutical products, including Entocort EC for Crohn's disease and Imuran for rheumatoid arthritis management. The company's commitment to innovation and precision healthcare enables physicians to optimize treatment strategies and enhance patient outcomes.

Mamotest is a company focused on improving breast cancer outcomes through a digital platform that leverages artificial intelligence. By democratizing access to early diagnosis and patient guidance, Mamotest aims to transform the care delivery process. The platform employs telediagnosis and ensures complete traceability of the patient journey, promoting a proactive approach to health rather than a reactive one. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

IndyGeneUS AI is a Black-Owned and Service-Disabled Veteran-Owned Small Business specializing in genomics. The company is developing the world's largest blockchain-encrypted repository of clinical and genomic data specifically for indigenous and diasporic African populations. Utilizing proprietary technology, IndyGeneUS AI integrates multi-omics data, electronic healthcare records, and scientific literature to identify novel signature sequences, biomarkers, and polygenic risk scores. This extensive data repository aims to enhance disease prevention, detection, and drug discovery while promoting clinical disease management and precision health equity. By focusing on the unique genomic characteristics of these populations, the company seeks to improve the efficiency and quality of healthcare delivery.

TransVoyant, Inc. is an analytics company specializing in predictive solutions that leverage real-time big data streams to provide insights for various industries. Founded in 2011 and headquartered in Alexandria, Virginia, the company collects, cleanses, and analyzes over one trillion events daily from diverse sources, including IoT devices, sensors, and satellites. TransVoyant's offerings include Precise Predictive Intelligence (P2I) for behavior analysis and anomaly detection, Continuous Decision Intelligence (CDI) for industry-specific solutions, and Precise Predictive Logistics (P2L), which tracks the real-time behavior and location of various assets such as aircraft, vessels, and vehicles. The company's advanced machine learning algorithms empower Fortune 500 companies, niche consulting firms, and government agencies to anticipate and mitigate potential disruptions from factors like weather events, supply chain issues, and competitive behavior. TransVoyant has established strategic partnerships with major organizations to enhance its capabilities in delivering actionable insights.

Turbine Ltd is a biotechnology company based in Budapest, Hungary, founded in 2015. It specializes in the development of computational models that predict biological and clinical outcomes to aid in cancer drug development. Utilizing its proprietary Simulated Cell technology alongside artificial intelligence, Turbine focuses on understanding the intricate mechanisms of cancer. This approach facilitates the discovery of novel protein targets and precision biomarkers, enhancing the translation of research to patient care. The company also creates cancer combination therapies that clarify the underlying biology of diseases and personalize treatment options. By leveraging bioinformatics and network medicine, Turbine effectively simulates complex interventions, allowing for the screening of numerous drug combinations on simulated cells. This innovative process aims to provide cancer patients with low-cost and effective treatment plans.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

CancerIQ is a precision health technology company that provides a platform designed to assist healthcare providers in identifying and managing patients at high risk for cancer. The platform features predictive analytics and screening tools to help clinicians detect at-risk patients early. It includes a comprehensive library of evidence-based guidelines and risk models, which aids providers in interpreting data and guiding patients toward appropriate genetic testing, screening, and treatment interventions. Additionally, CancerIQ offers a digital genetic test ordering system and patient management tools, enhancing clinician efficiency and improving patient outcomes by facilitating early cancer detection and adherence to evidence-based care strategies.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

TagNTrac is an IoT platform that provides integrating multimode technologies typically hardware, software, and data to build solutions.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating serious and rare diseases. Based in Cambridge, Massachusetts, the company focuses on developing novel biotherapeutics that modulate growth factors related to bone, muscle, fat, and vascular health. Its product portfolio includes luspatercept-aamt, marketed as REBLOZYL, for treating anemia in adult patients with beta-thalassemia, and candidates such as Sotatercept for pulmonary arterial hypertension. Additionally, Acceleron is advancing ACE-083, a neuromuscular treatment currently in Phase II trials for Charcot-Marie-Tooth disease. The company collaborates with partners like Celgene Corporation and Fulcrum Therapeutics to develop therapies targeting specific pathways in pulmonary diseases. Founded in 2003, Acceleron Pharma continues to focus on creating innovative treatments for conditions such as cancer-related bone loss, muscle degeneration, and metabolic disorders.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Mamotest is a company focused on improving breast cancer outcomes through a digital platform that leverages artificial intelligence. By democratizing access to early diagnosis and patient guidance, Mamotest aims to transform the care delivery process. The platform employs telediagnosis and ensures complete traceability of the patient journey, promoting a proactive approach to health rather than a reactive one. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates.

M2Gen is a health informatics solutions company established in 2006 at the Moffitt Cancer Center in Tampa, Florida. The company specializes in advancing precision medicine by integrating and analyzing clinical and molecular data. Its integrated platform helps identify patient susceptibility to diseases, predict drug responses, and match patients with optimal therapies for better treatment outcomes. M2Gen also offers a portfolio designed for biopharmaceutical companies to discover new targets and biomarkers, enhance clinical trial design and enrollment, and conduct post-market analysis. One of its key initiatives is the Total Cancer Care Protocol, which studies patients throughout their lifetime, and the ORIEN Avatar Research Program, which focuses on individuals with advanced disease and limited treatment options. M2Gen operates as a subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

Zapata Computing, Inc. is a quantum software company that specializes in developing computing solutions for various industries, including finance, healthcare, logistics, and pharmaceuticals. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company offers Orquestra, a software platform that enables users to compose quantum workflows and execute them on both quantum and classical hardware. This platform facilitates simulations, optimizations, and machine learning applications, allowing for efficient management of complex tasks across different environments. As a spin-out from Harvard University, Zapata Computing leverages advanced computational techniques grounded in quantum physics to provide hardware-agnostic solutions tailored to enterprise organizations.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

Volansi, Inc. is a logistics and transportation company that specializes in the manufacture of heavy-payload drones for various sectors, including commercial, defense, and humanitarian applications. Founded in 2015 and headquartered in Concord, California, Volansi designs and operates unmanned aerial vehicles to facilitate time-critical deliveries over long distances. The company targets industries such as construction, oil and gas, mining, and healthcare, providing on-demand and point-to-point shipment solutions. Its drones are engineered to deliver goods along fixed routes, addressing specific challenges related to time and cost, thereby enabling enterprises to optimize their logistics and improve operational efficiency.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Zapata Computing, Inc. is a quantum software company that specializes in developing computing solutions for various industries, including finance, healthcare, logistics, and pharmaceuticals. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company offers Orquestra, a software platform that enables users to compose quantum workflows and execute them on both quantum and classical hardware. This platform facilitates simulations, optimizations, and machine learning applications, allowing for efficient management of complex tasks across different environments. As a spin-out from Harvard University, Zapata Computing leverages advanced computational techniques grounded in quantum physics to provide hardware-agnostic solutions tailored to enterprise organizations.

Tasso, Inc. is a Seattle-based company founded in 2012 that specializes in manufacturing blood sample collection devices designed for patient convenience. The company's innovative devices enable individuals to collect their own blood samples safely and easily at home, eliminating the need for clinic visits. These disposable, compact devices feature interchangeable cartridges that ensure proper blood preparation immediately upon sample collection. By allowing patients to manage their blood sampling process, Tasso aims to streamline blood-based diagnostics and enhance the overall experience of medical testing.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing applications and games aimed at managing chronic health conditions and improving patient adherence. Established in 2008, Ayogo employs behavioral psychology and social gaming principles to enhance health outcomes, serving a diverse clientele that includes insurers, healthcare providers, and pharmaceutical companies. The company's flagship product, GoodLife, is a customizable platform featuring gamification elements, incentives, and social interaction, while its suite of Alternate Reality Games integrates online and real-world experiences to facilitate learning. Ayogo's platform is designed to tailor content and support to individual psychosocial factors, promoting patient engagement by fostering activation and adherence to therapy. With a collaborative approach involving patients and clients, Ayogo emphasizes thoughtful innovation within its creative studio environment.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of targeted therapeutics for cancer and rare diseases. Founded in 1993 and headquartered in Burlington, Massachusetts, the company employs its ArQule Kinase Inhibitor Platform to design and develop novel small molecule drugs. ArQule's pipeline includes several investigational therapies, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase for B-cell malignancies; miransertib, an AKT inhibitor for advanced endometrial cancer; and ARQ 75, also targeting AKT in solid tumors. Additionally, Derazantinib is a multi-kinase inhibitor in clinical trials for intrahepatic cholangiocarcinoma. The company has established license agreements with Basilea Pharmaceutica and Roivant Sciences for its therapeutic candidates. As of January 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

She's Well is a fertility management service that utilizes a subscription model to assist individuals and couples in starting families at their own pace. The company partners with leading fertility centers to provide financial plans for various services, including fertility testing, IVF, egg freezing, and sperm freezing. By adopting an on-demand concierge care approach, She's Well aims to simplify the often complex and isolating fertility journey. With one in six couples facing challenges in conception and a growing trend of delayed childbirth, She’s Well addresses a significant gap in infertility services, which currently reach only a small percentage of those in need. Typical costs for treatments like IVF can be prohibitively high, often ranging from $12,000 to $20,000, with additional expenses for genetic testing. She's Well seeks to make fertility care more affordable and accessible, promoting a future where family planning is not constrained by biological timelines and where comprehensive care options are available to all who wish to conceive.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

CIOX Health, LLC is a healthcare technology company that operates a platform designed to manage and share patient medical records securely. Established in 1976, the company offers services such as information release, denials prevention, coding and education, imaging, clinical abstraction, oncology data management, medical record retrieval, second level review coding, risk adjustment solutions, and AudaPro, an audit tool for centralizing processes. Serving healthcare providers, health plans, real-world data companies, government agencies, law firms, life insurance companies, and patients, CIOX aims to improve healthcare outcomes by transforming shared information into actionable insights. As of 2021, the company operates as a subsidiary of CT Technologies Holdings, LLC following its merger with Datavant.

Tilos Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in creating anti-LAP antibodies that target the Latency Associated Peptide of TGF beta, which plays a critical role in regulating immune responses. Tilos Therapeutics primarily concentrates on modulating regulatory T cells and effector cells to enhance the immune system's ability to combat diseases. By leveraging these immunological pathways, Tilos aims to provide innovative treatments that enable patients to initiate therapy more rapidly, ultimately leading to improved medical outcomes.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, specializing in the development of therapeutics that target bone-related diseases. The company utilizes a unique prodrug platform that delivers bi-specific small-molecule therapeutics selectively to bone tissue, minimizing side effects associated with systemic exposure. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic, designed to potentially reverse bone loss linked to conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary technology overcomes the challenges of delivering medications to the difficult-to-treat bone environment, which often requires high drug doses and can lead to significant side effects. Through pre-clinical in-vivo models, the effectiveness of this bone-targeting system has been confirmed, positioning Mesentech to address various low-bone-density disorders and enhance bone healing outcomes. The company was incorporated in 2013 and continues to innovate in the field of bone therapeutics.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for cancer and other serious conditions. Its lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, PT2977 is being tested in various combinations and settings, including von Hippel-Lindau disease associated renal cell carcinoma and glioblastoma multiforme. The company is also working on PT2567, another HIF-2a inhibitor in preclinical development targeting non-oncology conditions such as pulmonary arterial hypertension. Founded in 2010 by Steven L. McKnight and supported by the Cancer Prevention Research Institute of Texas and experienced investors, Peloton aims to leverage its scientific collaborations and robust pipeline to establish itself as a leading biotech firm in cancer drug discovery and development.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

Clinithink Ltd is a healthcare software company based in Bridgend, United Kingdom, that specializes in cloud-based data analytics solutions. Founded in 2009, the company has developed a platform known as CLiX, which employs Natural Language Processing (NLP) to convert unstructured clinical narratives into structured data. This technology allows healthcare providers, pharmaceutical companies, and content vendors to collect and analyze clinical trial data effectively. Clinithink's products include CLiX ENRICH, which facilitates the indexing and recording of clinical trial data in a preferred narrative format, and CLiX RARE, aimed at diagnosing genetic disorders in newborns. Through its innovative approach, Clinithink supports healthcare applications in data analytics, coding, and decision-making.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Kytopen is a developer of a cell therapy platform that focuses on the non-viral delivery of molecules into challenging immune cells. The company's innovative technology integrates microfluidics and automation to streamline the delivery process, making it faster, easier, and more cost-effective. Kytopen's automated cell engineering platform enables researchers to produce healthy and functional engineered cells rapidly, maintaining their health and functionality. By combining continuous fluid flow with electric fields, Kytopen enhances the efficiency of payload delivery to primary cells, supporting advancements in biology and paving the way for innovative cell and gene therapies.

Antelliq specializes in animal intelligence solutions that enhance the management of livestock, pets, and fish through innovative identification, traceability, and monitoring technologies. The company offers a range of products that provide critical data to veterinarians, farmers, and pet owners, thereby improving the health and well-being of animals. Operating under well-known brands such as Allflex, Sure Petcare, and Biomark, Antelliq has a global presence, serving customers in over 100 countries and employing more than 1,900 people. With a history of over 60 years in the industry, Antelliq emphasizes real-time data to enable better herd management for farmers and offers smart devices to help pet owners monitor their pets' health. The company also engages in conservation efforts, supporting the protection of natural environments and wildlife. Antelliq’s innovation is driven by its four specialized Innovation Centers located in Israel, France, the UK, and the US, which focus on different aspects of animal intelligence technology, leveraging extensive research and development expertise to continuously improve animal health solutions.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Pelago, formerly known as Quit Genius, is a leading virtual clinic focused on substance use management, particularly for tobacco, alcohol, and opioids. The company aims to transform support for substance use by offering education, management skills, and opportunities for positive change to individuals struggling with addiction. Pelago provides employers with a means to offer on-demand, personalized support for employees seeking healthier lifestyles. Its platform utilizes cognitive behavioral therapy (CBT) to address the psychological aspects of addiction, helping users identify triggers and access support through animated videos, interactive exercises, and audio sessions. This approach allows individuals to work at their own pace with the assistance of a personalized coach. Pelago's services seamlessly integrate with health plans, pharmacy benefit managers, and wellness platforms, and the company has successfully supported over 750,000 members in managing their substance use and improving their overall well-being.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Viralytics Limited is an Australian biotechnology company dedicated to the development and commercialization of oncolytic immunotherapies aimed at treating various types of cancer. The company's leading product, CAVATAK, is a proprietary formulation of a common cold virus currently undergoing Phase Ib clinical trials for melanoma, lung, and bladder cancer, and is in Phase II trials for late-stage melanoma. Additionally, CAVATAK is being explored in preclinical studies for several other cancers, including prostate, breast, and pancreatic cancer. Viralytics is also working on another product, EVATAK, targeting ovarian, prostate, and gastric cancers. With headquarters in Sydney and research operations in Newcastle, the company utilizes the cancer-destroying properties of benign viruses to enhance treatment effectiveness and minimize side effects. Formerly known as Psiron Ltd., Viralytics changed its name in December 2006 and now operates as a subsidiary of Merck & Co. Inc.

electroCore, Inc. is a commercial stage medical device company based in Basking Ridge, New Jersey, specializing in bioelectronic medicine. The company focuses on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies, primarily aimed at enhancing patient outcomes in neurology. Its flagship product, gammaCore, is a prescription-only device designed for the acute treatment of pain associated with migraine and episodic cluster headaches, as well as for the preventive treatment of these conditions in adult patients. The gammaCore Sapphire is a rechargeable and reloadable handheld system that can be prescribed on a monthly basis for multi-year use. Founded in 2005, electroCore aims to address various neurological conditions through its innovative therapeutic platform.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

PatientSafe Solutions, located in San Diego, California, specializes in innovative mobile solutions for point-of-care healthcare delivery. The company's flagship product, the PatientTouch System, enhances the productivity and safety of care teams by streamlining workflows on a single handheld device. This wireless clinical mobility solution integrates various functionalities, including positive patient identification, care interventions, and real-time communication, which are essential for improving patient safety and clinical outcomes. The PatientTouch System is designed with hospital-grade durability and features a high-performance barcode scanner, a full-shift battery, and an intuitive interface, making it suitable for frontline clinicians. By consolidating communication and workflows, PatientSafe Solutions enables hospitals to minimize harm, reduce waste, and enhance overall productivity in care delivery. The company's contributions to healthcare technology have garnered recognition, including being listed among the top venture-backed healthcare companies.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

Serimmune Inc. is a biotechnology company focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014 and based in Goleta, California, the company utilizes its serum epitope repertoire analysis (SERA) technology platform, which integrates bacterial display peptide libraries, sequencing, machine learning, and custom bioinformatics. This platform enables the comprehensive profiling of antibody repertoires and the identification of antigens and epitopes linked to various health conditions, including infections, allergens, microbiome organisms, autoimmune diseases, and cancers. By decoding the human immune response, Serimmune aims to empower the creation of innovative diagnostics, vaccines, and therapeutic solutions.

ClearDATA Networks is a company that specializes in cloud computing and information security services tailored for the healthcare industry. Based in Austin, Texas, ClearDATA offers a HITRUST-certified cloud platform designed to protect sensitive patient data and support critical healthcare applications across major public cloud environments. Its comprehensive solutions include cloud security posture management and managed detection and response services, ensuring compliance with industry regulations and safeguarding personal health information. By providing robust data management capabilities and multi-cloud expertise, ClearDATA empowers healthcare organizations to scale their IT infrastructure effectively, allowing them to focus on enhancing healthcare delivery and improving patient outcomes.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Arcadia Solutions, LLC is a healthcare technology company based in Burlington, Massachusetts, specializing in electronic health record (EHR) data aggregation and analytics. Founded in 2002, Arcadia provides a suite of services and proprietary software aimed at large healthcare providers, payors, accountable care organizations, and health information exchanges. The company offers various IT services, including EHR implementation and optimization, performance management, and information security solutions. Additionally, Arcadia develops customizable tools for planning and maintaining health IT infrastructures, which include monitoring services to evaluate key performance indicators and manage technology lifecycle needs. By integrating diverse healthcare data into a unified platform, Arcadia enables organizations to derive actionable insights that enhance care, support research, and drive strategic growth while ensuring financial success.